Innate Pharma SA (NAS:IPHA)

Full Year 2025 Innate Pharma SA Earnings Call Transcript

Mar 26, 2026 / 01:00 PM GMT

Release Date Price: $1.25 (-2.34%)

Transcript

Key Points

Positve

Innate Pharma SA (IPHA) has received FDA clearance to proceed with the Telemax 3 phase 3 trial for lacutamab in CTCL, with initiation expected in the second half of 2026.
IPH 4,502 is showing early signs of anti-tumor activity in heavily pretreated patients, including those with urothelial cancer, and has a favorable safety profile.
Monalizumab, in partnership with AstraZeneca, is progressing with the Pacific 9 phase 3 trial data readout expected in the second half of 2026.
The company has streamlined its organization to support efficient decision-making and disciplined capital allocation.
Innate Pharma SA (IPHA) has a cash position of 44.8 million, providing funding visibility until the end of the third quarter of 2026.

Negative

Operating expenses were 63 million, with a significant portion related to R&D, reflecting high costs associated with ongoing studies.
Revenue and other income amounted to only 9 million, indicating limited income generation from current operations.
The company is still in the process of evaluating financing options for the phase 3 study of lacutamab, indicating potential funding challenges.
The collaboration revenue from the monalizumab program has dropped significantly, reflecting a shift in project management to AstraZeneca.
There is a significant therapeutic gap in the post-EV setting for urothelial cancer, highlighting unmet needs that IPH 4,502 aims to address.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IPH.PA - Innate Pharma SA
Full Year 2025 Innate Pharma SA Earnings Call
Mar 26, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for joining us and welcome to the Innate Farmer Full Year 2025 earnings call. After today's prepared remarks, we will host a question-and-answer session.

If you would like to ask a question, please raise your hand. If you have dialed into today's call, please press 9 to raise your hand and 6 to unmute. I will now hand the conference over to Stephanie Corn, Vice President of Investor Relations, communications and commercial strategy at Innate Parma. Please, Stephanie, go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.